Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Body composition changes after levosimendan in advanced heart failure
2018-001623-39Phase 4Completed
- Sponsor
- Verein zur Förderung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und Gefäßkrankheiten
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of levosimendan in heart failure (HF) (2 arms), sponsored by Verein zur Förderung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und Gefäßkrankheiten. Primary endpoint: Improvement of body composition and hemodynamic parameters after levosimendan treatment. Started May 2018; status: completed.
02
Drugs
levosimendan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2018-001623-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001623-39.